扶正抗癌方联合NP方案治疗中晚期非小细胞肺癌临床研究

【作者】 龙鑫；

【导师】 李世杰；

【作者基本信息】 成都中医药大学 ， 中西医结合肿瘤防治， 2008， 硕士

【摘要】 目的:研究扶正抗癌方联合NP化疗方案治疗中晚期非小细胞肺癌的近期疗效及对化疗的减毒增效的作用。方法:将52例Ⅲ-Ⅳ期非小细胞肺癌住院患者,随机分为两组,其中观察组27例,对照组25例,两组均给予NP方案的全身化疗,观察组加服扶正抗癌方并随证加减。连续观察两个化疗周期后,比较两组治疗前后肿瘤病灶、症状、体重、生活质量卡氏评分、免疫功能、肿瘤标志物CEA的变化和毒副反应的情况。结果:扶正抗癌方加减配合化疗在改善临床症状、稳定并增加体重、提高生活质量、减轻血液和消化系统毒副反应及提高机体免疫功能方面,与单纯化疗组相比具有显著差异(P＜0.05):但在减小和稳定病灶、降低肿瘤标志物CEA的水平方面,与单纯化疗组相比无显著性差异(P＞0.05);两组对肝、肾功能的损害都不明显。结论:扶正抗癌方加减配合NP化疗治疗中晚期非小细胞肺癌,能够减轻化疗的毒副反应,稳定肿瘤病灶,改善患者的生活质量,值得进一步深入研究。更多还原

【Abstract】 Objective:To study the curative effect in the near future and increase efficiency and reduce toxicity during chemotherapy,according to treat mid-advanced non-small cell lung cancer(NSCLC) by "FuZhengKangAi Formula" combined with chemotherapy (NP regimen).Methods:52 subjects with mid-advanced NSCLC were randomly divided into two groups,27 patients in the treated group were administered with "FuZhengKangAi Formula" and chemotherapy(NP regimen),25 in the control group with chemotherapy alone.Objective effects and the changes of subjective symptoms were studied during two periods of treatment.Results:After two periods of treatment,the subjective symptoms、KPS、body weights、the tumor mark(CEA)、immune parameters were all significantly improved in the treated group,better than in the control one.But there was no difference between two groups on the size of focus,the toxicity occurent rate and toxic degree ware slighter in the treated group than in the control one.Conclusion:"FuZhengKangAi Formula" and chemotherapy(NP regimen)have plusly curative effect on treating mid-advanced NSCLC,it can alleviate adverse effect of chemotherapy,cause the tumor lump to stable,and improve patient’s quality of life, which plays the synergized and reduce toxicity action,and worthing to further deep research.更多还原